Inotuzumab ozogamicin

Generic Name
Inotuzumab ozogamicin
Brand Names
Besponsa
Drug Type
Biotech
Chemical Formula
-
CAS Number
635715-01-4
Unique Ingredient Identifier
P93RUU11P7
Background

Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (Gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting ...

Indication

Indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL).

Associated Conditions
Refractory B-cell precursor acute lymphoblastic leukemia, Relapsed B cell precursor Acute lymphoblastic leukemia
Associated Therapies
-
Clinical Trials
Related News

Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL

First Posted Date
2018-03-09
Last Posted Date
2022-11-02
Lead Sponsor
Nicola Goekbuget
Target Recruit Count
65
Registration Number
NCT03460522
Locations
🇩🇪

Universität Erlangen, Erlangen, Germany

🇩🇪

Klinikum Augsburg, Augsburg, Germany

🇩🇪

University Hospital of Frankfurt, Frankfurt, Germany

and more 11 locations

Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

First Posted Date
2018-02-22
Last Posted Date
2024-12-10
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT03441061
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

First Posted Date
2017-05-12
Last Posted Date
2024-10-26
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
310
Registration Number
NCT03150693
Locations
🇺🇸

Alaska Women's Cancer Care, Anchorage, Alaska, United States

🇺🇸

Anchorage Oncology Centre, Anchorage, Alaska, United States

🇺🇸

Katmai Oncology Group, Anchorage, Alaska, United States

and more 456 locations

Inotuzumab Ozogamicin - PF-05208773

First Posted Date
2017-04-25
Last Posted Date
2020-05-18
Lead Sponsor
Pfizer
Registration Number
NCT03127605

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

Phase 1
Recruiting
Conditions
Acute Lymphocytic Leukemia
Interventions
Drug: Inotuzumab Ozogamicin
First Posted Date
2017-04-07
Last Posted Date
2024-07-23
Lead Sponsor
Leland Metheny
Target Recruit Count
44
Registration Number
NCT03104491
Locations
🇺🇸

The University of Kansas Cancer Center, Westwood, Kansas, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

and more 4 locations

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

First Posted Date
2016-12-05
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
80
Registration Number
NCT02981628
Locations
🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Providence Alaska Medical Center, Anchorage, Alaska, United States

🇺🇸

Banner Children's at Desert, Mesa, Arizona, United States

and more 153 locations

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

First Posted Date
2016-08-24
Last Posted Date
2024-12-10
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
80
Registration Number
NCT02877303
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy

First Posted Date
2012-09-05
Last Posted Date
2022-05-18
Lead Sponsor
University College, London
Target Recruit Count
129
Registration Number
NCT01679119
Locations
🇬🇧

North Hampshire Hospital, Basingstoke, United Kingdom

🇬🇧

West Suffolk Hospital, Bury St Edmunds, United Kingdom

🇬🇧

University Hospital, Coventry, Coventry, United Kingdom

and more 37 locations

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

First Posted Date
2012-03-28
Last Posted Date
2019-01-09
Lead Sponsor
Pfizer
Target Recruit Count
326
Registration Number
NCT01564784
Locations
🇺🇸

University of Kansas Cancer Center, Westwood, Kansas, United States

🇺🇸

Investigational Drug Services - UC San Diego Moores Cancer Center, La Jolla, California, United States

🇺🇸

UC San Diego Medical Center - La Jolla, La Jolla, California, United States

and more 189 locations

Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma

First Posted Date
2012-02-20
Last Posted Date
2016-06-07
Lead Sponsor
Cristiana Sessa
Target Recruit Count
25
Registration Number
NCT01535989
Locations
🇨🇭

Oncology Institute of Southern Switzerland, Bellinzona, Ticino, Switzerland

🇨🇭

InselSpital, Universitätsspital Bern, Bern, Switzerland

🇨🇭

Kantonsspital St.Gallen, San Gallen, Switzerland

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy